+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 19Years - 70Years
All Genders
ID05093881

Long-Term Safety Follow-Up Study of Cellgram-LC Treatment in Patients with Alcoholic Liver Cirrhosis from the PMC-P-07 Trial

Led by Pharmicell Co., Ltd. · Updated on 2026-09-21

100

Participants Needed

14

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

This observational study focuses on patients with alcoholic liver cirrhosis who previously received Cellgram-LC treatment in the PMC-P-07 clinical trial. It aims to learn about the long-term safety of Cellgram-LC by monitoring key outcomes such as adverse events of special interest AESI and the occurrence of liver transplantation over five years following treatment. Participants who took part in the earlier PMC-P-07 study and received Cellgram-LC will be invited to join this follow-up study. The study involves annual telephone visits over a five-year period after the initial Cellgram-LC administration to collect information on any AESI or liver transplantation events. During the study, participants will be contacted by phone once a year to report health status related to AESI and liver transplantation. The research team will assess these outcomes annually to understand the long-term safety profile of Cellgram-LC. This follow-up period lasts five years from the date of Cellgram-LC administration, allowing close monitoring of participants health over time.

CONDITIONS

Brief Title

Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC

Research Team

Y

YUJEONG KIM

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here